Event dossier

FDA approves higher dose version of weight loss drug Wegovy as Novo Nordisk tries to win back market share

The high-dose Wegovy helped patients with obesity lose an average 20.7% of their weight after 72 weeks in a phase three trial.

0 reports0 sourcesMar 19, 2026, 5:48 PM
FilterEvent feed
Clustered coverageAll sources
Coverage timeline0
Coverage timeline

Coverage timeline

Ranked reports inside the event cluster. Open any publisher link to read the original coverage.

No linked coverage has been stored for this event yet.
Related events

Related events

Nearby clusters pulled from title, summary, and keyword similarity in PostgreSQL.

El Psy Congroo Newswire